Anaptysbio vs Puma Biotechnology
Anaptysbio and Puma Biotechnology are similar in size: $235m and $228m of revenue in their latest fiscal years. Anaptysbio grew faster (157.0% against -0.9%). Puma Biotechnology kept more of each dollar of sales as profit: a net margin of 13.6% against -5.6%. Anaptysbio carries less debt relative to equity (0.0% against 17.4%).
| Latest fiscal year | AnaptysbioANAB, 2025 | Puma BiotechnologyPBYI, 2025 |
|---|---|---|
| Revenue | $235m | $228m |
| Revenue growth | 157.0% | -0.9% |
| Net income | −$13.2m | $31.1m |
| Operating margin | 96.7% | 16.3% |
| Net margin | -5.6% | 13.6% |
| Return on equity | -24.5% | 28.0% |
| Free cash flow | $19.6m | $41.7m |
| Cash | $138m | $29.6m |
| Total debt | $0 | $22.7m |
| Debt to equity | 0.0% | 17.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $68.6m | — |
| Employees | 104 | 179 |
| Market value | $1.42bn | $521m |
| Price vs our value range | — | Below our value range |
| Moat score | 13 (Weak) | 47 (Moderate) |
| Insider trades, 12 months | 0 buys, 42 sales | 0 buys, 17 sales |